EGFR and lung adenocarcinoma: We found that caspase-9 inhibitor (intrinsic apoptosis inhibitor: z-LEHD-fmk) and pan-caspase inhibitor (z-VAD-fmk) reduced approximately 8%, 18%, and 4% (4%–18%) of cell deaths in the EGFR-sensitive lung adenocarcinoma cells, while necrostatin-1 (necroptosis inhibitor; nec-1) salvaged the most cell deaths in lung adenocarcinoma (Figures 6A–C).